---
title: "综述 | Neurol-Oncol 2025 | 脑转移TME"
date: 2025-05-16T04:50:54Z
draft: ["false"]
tags: [
  "fetched",
  "NeuroLab Precision"
]
categories: ["Acdemic"]
---
综述 | Neurol-Oncol 2025 | 脑转移TME by NeuroLab Precision
------
<div><p><span><span leaf=""><img data-imgfileid="100000788" data-ratio="0.2759259259259259" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJRPyNosNCz8WEQWr38CFibRn57iaThyl3PLY4KjCiavnuRj5OTvqicg5aA6icAOVrcBuGDrYusNNaibmXaw/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/sz_mmbiz_png/RbQJibkicroJRPyNosNCz8WEQWr38CFibRn57iaThyl3PLY4KjCiavnuRj5OTvqicg5aA6icAOVrcBuGDrYusNNaibmXaw/640?wx_fmt=png&amp;from=appmsg"></span></span></p><h3><span leaf=""><span textstyle="">Introduction逻辑框架</span></span></h3><p><span><span leaf=""><span textstyle="">临床需求（BrM高发且难治）</span></span><span><span leaf=""><span textstyle="">  </span></span></span><span leaf=""><br></span><span leaf=""><span textstyle="">提出机制假说（TME驱动治疗抵抗）</span></span><span><span leaf=""><span textstyle="">  </span></span></span><span leaf=""><br></span><span leaf=""><span textstyle="">阐述脑-MME独特性（结构+免疫）</span></span><span><span leaf=""><span textstyle="">  </span></span></span><span leaf=""><br></span><span leaf=""><span textstyle="">聚焦免疫细胞多样性（从"豁免"到"动态互作"的范式转变）</span></span><span><span leaf=""><span textstyle="">  </span></span></span><span leaf=""><br></span><span leaf=""><span textstyle="">引出全文主题：解析免疫组分功能并探索靶向策略</span></span></span></p><p><span><span leaf=""><img data-imgfileid="100000790" data-ratio="0.9453703703703704" data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/RbQJibkicroJRPyNosNCz8WEQWr38CFibRnickskJbG3avmVpibq4xzldMxVqq7AkxospExlBa1vXu7Hdfs76xZCOng/640?wx_fmt=jpeg&amp;from=appmsg" data-type="jpeg" data-w="1080" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/RbQJibkicroJRPyNosNCz8WEQWr38CFibRnickskJbG3avmVpibq4xzldMxVqq7AkxospExlBa1vXu7Hdfs76xZCOng/640?wx_fmt=jpeg&amp;from=appmsg"></span></span></p><h2><span leaf=""><span textstyle="">图1 脑转移微环境中肿瘤与免疫相互作用的简化概述</span></span></h2><h2><span><span leaf=""><span textstyle="">一、髓系</span></span></span><span></span></h2><h3><span><span leaf=""><span textstyle="">A. 肿瘤相关巨噬细胞（TAMs）</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. TAMs的组成与异质性</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">来源</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CNS驻留型</span></span></span><span><span leaf=""><span textstyle="">（占主导）：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">小胶质细胞</span></span></span><span><span leaf=""><span textstyle="">（大脑原生免疫细胞，具可塑性，参与早期免疫防御）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">BAMs</span></span></span><span><span leaf=""><span textstyle="">（脑边界巨噬细胞，抗原提呈能力更强，但功能研究较少）。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">浸润型</span></span></span><span><span leaf=""><span textstyle="">（MDMs）：外周单核细胞招募至肿瘤核心，随病程进展逐渐增多。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">标记物挑战</span></span></span><span><span leaf=""><span textstyle="">：传统标记（如CX3CR1、TMEM119）难以区分小胶质细胞与MDMs，需依赖新标记（如CD49D、CD141）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. TAMs的动态表型</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">小胶质细胞</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">表现为未成熟炎症表型（上调促炎因子如TNF、IL-1β，但同时表达抗炎基因如VEGFA、LGALS1）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">失去稳态标记（如P2RY12），形态变为活化星状。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MDMs</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">更异质，含促炎（IFNγ签名）和抗炎（M2样标记如CD163、IL10）亚群。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">高表达抗原提呈相关分子（如MHC-II、CD1C），类似树突细胞。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. TAMs的功能双刃剑</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">促转移作用</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">早期：小胶质细胞通过WNT、CXCR4等通路助肿瘤细胞穿越血脑屏障（BBB）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">晚期：MDMs分泌组织蛋白酶S等促 colonization；免疫抑制分子（如PD-L1、IDO）抑制T细胞功能。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抗肿瘤潜力</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">小胶质细胞可吞噬肿瘤细胞，招募NK/T细胞（如分泌CCL3/4）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">LPS或他莫昔芬可激活其杀伤能力，但随病程逐渐丧失。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 治疗启示</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">时间窗口</span></span></span><span><span leaf=""><span textstyle="">：早期靶向小胶质细胞（如抑制WNT）可能阻断转移，晚期需克服MDMs的免疫抑制。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">表型调控</span></span></span><span><span leaf=""><span textstyle="">：促炎激活（如IFNγ）或抑制免疫检查点（如PD-L1）是潜在策略。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：TAMs在脑转移中扮演复杂角色，从早期防御到晚期促瘤，其动态表型和功能异质性提示需精准干预策略。</span></span></span></p><p><span><p><span leaf=""><img data-src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/RbQJibkicroJRPyNosNCz8WEQWr38CFibRna1YbibWvuakyzalY2Pbz7ia9uQ8JZQ2kkiaJhq7pcicCbwYmlKs62TGSEw/640?wx_fmt=jpeg&amp;from=appmsg" alt="Functional contribution of TAMs along the metastasis cascade. Microglia contribute to the establishment of the premetastatic niche and aid tumor cell extravasation by altering the BBB. During early metastatic establishment, microglia are reprogrammed by tumor-derived signals to facilitate invasion and colonization. Monocytes attracted to the metastatic site differentiate into MDMs further aiding metastatic growth. Finally, in the surrounding of established metastases, TAMs attract lymphocytes and convey immunosuppression." data-ratio="0.7241666666666666" data-type="jpeg" data-w="3600" data-backw="578" data-backh="419" data-imgfileid="100000789" src="https://mmbiz.qpic.cn/sz_mmbiz_jpg/RbQJibkicroJRPyNosNCz8WEQWr38CFibRna1YbibWvuakyzalY2Pbz7ia9uQ8JZQ2kkiaJhq7pcicCbwYmlKs62TGSEw/640?wx_fmt=jpeg&amp;from=appmsg"></span></p></span></p><h3><span leaf=""><span textstyle="">图2 TME中髓系的级联反应</span></span></h3><h3><span><span leaf=""><br></span></span></h3><h3><span><span leaf=""><span textstyle="">B. 中性粒细胞（Neutrophils）</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. 基本特征与临床关联</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">占比</span></span></span><span><span leaf=""><span textstyle="">：占外周血髓系细胞的50%~70%，是实体瘤中主要的炎症细胞之一。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">预后标志</span></span></span><span><span leaf=""><span textstyle="">：外周血</span></span></span><span><span leaf=""><span textstyle="">高中性粒/淋巴细胞比值（NLR）</span></span></span><span><span leaf=""><span textstyle="">与术后生存率降低相关。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 脑转移中的表型与功能</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">促转移表型</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫抑制</span></span></span><span><span leaf=""><span textstyle="">：高表达</span></span></span><span><span leaf=""><span textstyle="">PD-L1</span></span></span><span><span leaf=""><span textstyle="">（靠近PD1+ CD8+ T细胞）、</span></span></span><span><span leaf=""><span textstyle="">ARG1</span></span></span><span><span leaf=""><span textstyle="">，抑制抗肿瘤免疫。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">迁移浸润</span></span></span><span><span leaf=""><span textstyle="">：上调</span></span></span><span><span leaf=""><span textstyle="">ITGA3、CD177、CD15、CD11b</span></span></span><span><span leaf=""><span textstyle="">等迁移标记，促进肿瘤侵袭。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">血管生成</span></span></span><span><span leaf=""><span textstyle="">：富集于肿瘤血管周围，参与促血管微环境形成。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">趋化机制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肿瘤分泌</span></span></span><span><span leaf=""><span textstyle="">G-CSF</span></span></span><span><span leaf=""><span textstyle="">、</span></span></span><span><span leaf=""><span textstyle="">S100A8/9</span></span></span><span><span leaf=""><span textstyle="">招募中性粒细胞至转移前微环境，形成正反馈循环（S100A9持续高表达）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">炎症信号（如IL8、CXCL1）驱动其向肿瘤部位聚集。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 治疗策略</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向招募</span></span></span><span><span leaf=""><span textstyle="">：阻断趋化因子信号（如IL8/CXCL1抑制剂）。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">解除免疫抑制</span></span></span><span><span leaf=""><span textstyle="">：抑制PD-L1或ARG1活性。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">清除促瘤亚群</span></span></span><span><span leaf=""><span textstyle="">：选择性靶向高表达CD177或S100A9的中性粒细胞。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：中性粒细胞通过免疫抑制、促血管生成和炎症放大加速脑转移，靶向其招募或功能可成为潜在干预手段。</span></span></span></p><h3><span><span leaf=""><span textstyle="">C. 树突细胞（DCs）</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. DCs的核心功能</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">专职抗原提呈</span></span></span><span><span leaf=""><span textstyle="">：激活并调控T细胞介导的抗肿瘤免疫应答。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 脑转移中的DC亚群与特征</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD163+CD14+ DCs</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">高表达趋化因子，可能参与T细胞招募至肿瘤微环境。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">III型DCs</span></span></span><span><span leaf=""><span textstyle="">（见于黑色素瘤脑转移）：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">与T细胞激活及MHC分子表达相关，促进免疫应答。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">II型DCs</span></span></span><span><span leaf=""><span textstyle="">（多癌种脑转移中占主导）：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">分为两个功能互斥的亚群：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">迁移型</span></span></span><span><span leaf=""><span textstyle="">：高表达迁移相关受体（如CCR7）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抗原提呈型</span></span></span><span><span leaf=""><span textstyle="">：高表达MHC-II、共刺激分子（如CD80/CD86）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 治疗启示</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">增强DC功能</span></span></span><span><span leaf=""><span textstyle="">：通过疫苗或免疫佐剂（如TLR激动剂）提升抗原提呈效率。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向亚群</span></span></span><span><span leaf=""><span textstyle="">：选择性激活迁移型DCs以促进T细胞浸润，或抑制免疫抑制性DCs（如CD163+亚群）。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：DCs在脑转移中呈现功能异质性，既有促免疫激活的亚群，也存在潜在免疫抑制表型，精准调控其功能或可改善免疫治疗效果。</span></span></span><page></page></p><p><span><p><span leaf=""><span textstyle=""> </span></span></p></span></p><h2><span><span leaf=""><span textstyle="">二、淋系</span></span></span><span></span></h2><h3><span><span leaf=""><span textstyle="">A. T细胞</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. T细胞组成与分布特征</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">主要群体</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD8+ T细胞</span></span></span><span><span leaf=""><span textstyle="">：以效应记忆表型为主（具细胞毒性潜能），但普遍存在耗竭标志（PD1、TIM3、CTLA4）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD4+ T细胞</span></span></span><span><span leaf=""><span textstyle="">：包括Th1、Th17、细胞毒性亚群及T-regs（调节性T细胞），后者与免疫抑制和预后不良相关。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">空间分布</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肿瘤核心</span></span></span><span><span leaf=""><span textstyle="">：富集耗竭型CD8+ T细胞（高表达PD1）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肿瘤边缘</span></span></span><span><span leaf=""><span textstyle="">：更多记忆型CD8+ T细胞和效应T细胞。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 功能状态与免疫抑制</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">耗竭表型</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD8+ T细胞高表达共抑制分子（PD1、CTLA4、TIGIT等），且部分对非肿瘤抗原（如微生物抗原）反应。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">TOX+ CD8+ T细胞</span></span></span><span><span leaf=""><span textstyle="">：在黑色素瘤脑转移中鉴定，耗竭标志较低，可能保留部分功能。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD4+ T细胞功能失调</span></span></span><span><span leaf=""><span textstyle="">：表现为低反应性和无能状态，T-regs通过抑制微环境促进转移进展。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 动态交互与治疗启示</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">与TAMs的互作</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">小胶质细胞可诱导T细胞免疫抑制表型，但T细胞也可能激活TAMs的抗原提呈能力（如通过干扰素信号）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">治疗靶点</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">逆转耗竭</span></span></span><span><span leaf=""><span textstyle="">：联合免疫检查点抑制剂（如抗PD1+抗CTLA4）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向T-regs</span></span></span><span><span leaf=""><span textstyle="">：减少免疫抑制（如抗CCR4或IL-2受体靶向药物）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">激活γδ T细胞</span></span></span><span><span leaf=""><span textstyle="">：抑制促瘤的IL-17+亚群，增强细胞毒性亚群。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：脑转移中T细胞呈现高度异质性，耗竭和免疫抑制主导微环境，但部分亚群（如记忆型CD8+ T细胞）仍具抗肿瘤潜力。联合靶向T细胞功能调控与髓系免疫抑制是未来方向。</span></span></span></p><h3><span><span leaf=""><span textstyle="">B. B细胞</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. B细胞在脑转移中的分布特征</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">低浸润性</span></span></span><span><span leaf=""><span textstyle="">：相较于T细胞，B细胞在脑转移瘤中的浸润显著较少。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">浆细胞（CD138+）的积极关联</span></span></span><span><span leaf=""><span textstyle="">：瘤内高水平的浆细胞（抗体分泌型B细胞）与患者手术及放疗后的</span></span></span><span><span leaf=""><span textstyle="">总生存期延长</span></span></span><span><span leaf=""><span textstyle="">相关。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. B细胞与免疫治疗的关系</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫检查点抑制剂（ICI）的影响</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">临床前模型显示，PD-1抑制剂可促进B细胞在脑转移中的增殖。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">接受免疫治疗的黑色素瘤患者中，B细胞和浆细胞的比例更高，提示B细胞可能参与治疗响应。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">自身抗体的预测价值</span></span></span><span><span leaf=""><span textstyle="">：某些自身抗体水平可预测脑转移发生，但机制尚不明确。</span></span></span><page></page></p><h4><span><span leaf=""><span textstyle="">3. 潜在功能及研究空白</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抗肿瘤作用</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">浆细胞可能通过分泌抗体激活补体或抗体依赖性细胞毒性（ADCC）抑制肿瘤。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">B细胞可作为抗原提呈细胞（APC）激活T细胞反应。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">促瘤作用</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">某些B细胞亚群（如调节性B细胞，Bregs）可能通过分泌IL-10或TGF-β促进免疫抑制。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">未知领域</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">B细胞在脑转移中的具体亚群分布（如记忆B细胞、滤泡B细胞）及功能尚需单细胞测序等深入研究。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 治疗启示与未来方向</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">联合免疫治疗</span></span></span><span><span leaf=""><span textstyle="">：靶向PD-1/PD-L1可能协同增强B细胞抗肿瘤活性。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">B细胞靶向策略</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">促进浆细胞分化和抗体产生（如CD40激动剂）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抑制Bregs功能（如抗-IL-10抗体）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">生物标志物开发</span></span></span><span><span leaf=""><span textstyle="">：浆细胞或特定B细胞亚群可能作为免疫治疗响应的预测指标。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：尽管B细胞在脑转移中研究较少，现有证据提示其可能通过抗体分泌和免疫调节影响预后。未来需明确其亚群功能，并探索与免疫治疗的协同潜力。</span></span></span></p><h3><span><span leaf=""><span textstyle="">C. NK细胞及其他先天淋巴细胞</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. NK细胞的抗肿瘤潜力与脑转移微环境中的限制</span></span></span><page></page></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">核心功能</span></span></span><span><span leaf=""><span textstyle="">：NK细胞无需预先致敏即可杀伤肿瘤细胞，是抗肿瘤免疫的重要效应细胞。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">动物模型证据</span></span></span><span><span leaf=""><span textstyle="">：NK细胞缺失会导致脑转移负荷增加，提示其保护性作用。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肿瘤逃逸机制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">潜伏的播散性肿瘤细胞通过WNT信号通路下调NK细胞活化配体（如NKG2D配体），逃避免疫监视。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">脑转移微环境可能通过免疫抑制因子（如TGF-β）进一步抑制NK细胞功能。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 其他新兴淋巴细胞亚群的研究进展</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MAIT细胞（黏膜相关恒定T细胞）</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">小胶质细胞可向MAIT细胞提呈抗原，但其在脑转移中的分布和功能数据极少，现有研究主要集中于原发脑肿瘤。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">固有淋巴细胞（ILCs）</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">ILC2s缺失模型</span></span></span><span><span leaf=""><span textstyle="">中，脑内循环肿瘤细胞（CTCs）增加，提示ILC2s可能通过调控炎症抑制转移早期定植。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">ILC1s（类似NK细胞）和ILC3s（参与组织修复）的作用尚未明确。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 治疗启示与挑战</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NK细胞定向疗法</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">增强NK细胞活性：如抗NKG2A抗体（解除抑制）、IL-15激动剂（促进增殖）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">联合免疫检查点抑制剂（如抗PD-1）逆转耗竭。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向肿瘤逃逸机制</span></span></span><span><span leaf=""><span textstyle="">：抑制WNT通路或阻断TGF-β信号以恢复NK细胞识别能力。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">探索新兴亚群</span></span></span><span><span leaf=""><span textstyle="">：MAIT细胞和ILCs的代谢调控或可成为新靶点，但需进一步验证其在脑转移中的特异性作用。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 现存问题与未来方向</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">研究瓶颈</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">人脑转移样本中NK细胞和ILCs的丰度低，单细胞测序数据缺乏。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">动物模型与人类免疫微环境的差异需谨慎解读。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">关键科学问题</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NK细胞浸润脑转移的趋化机制（如CXCL12-CXCR4轴的作用）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MAIT细胞是否通过MR1依赖途径识别脑转移细胞。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：NK细胞是脑转移免疫防御的关键参与者，但受肿瘤微环境强烈抑制；MAIT细胞和ILCs的作用初现端倪。未来需结合临床样本与多组学技术，揭示这些细胞的动态调控网络，并开发针对性免疫疗法。</span></span></span></p><h2><span><span leaf=""><span textstyle="">三、脑转移瘤独特的免疫浸润微环境成因</span></span></span><span></span></h2><h3><span><span leaf=""><span textstyle="">A. 脑转移瘤（BrM）与原发性脑肿瘤及外周原发瘤的免疫差异</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. 脑转移微环境（BrM-ME） vs. 原发性脑肿瘤微环境（如胶质母细胞瘤）</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">巨噬细胞起源差异</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">原发性脑肿瘤</span></span></span><span><span leaf=""><span textstyle="">：TAMs以</span></span></span><span><span leaf=""><span textstyle="">小胶质细胞</span></span></span><span><span leaf=""><span textstyle="">（CNS原位）为主。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">脑转移瘤</span></span></span><span><span leaf=""><span textstyle="">：TAMs以</span></span></span><span><span leaf=""><span textstyle="">单核来源巨噬细胞（MDMs）</span></span></span><span><span leaf=""><span textstyle="">为主，且小胶质细胞可获MDM样表型。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫细胞分布特征</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">T细胞</span></span></span><span><span leaf=""><span textstyle="">：脑转移中T细胞浸润显著多于原发性脑肿瘤（后者仅限血管周围），但T-reg比例更高（占CD4+ T细胞的10%）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">中性粒细胞</span></span></span><span><span leaf=""><span textstyle="">：脑转移中浸润密度更高，浆细胞（CD138+）也更丰富。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NK细胞</span></span></span><span><span leaf=""><span textstyle="">：脑转移灶周围的NK细胞呈现</span></span></span><span><span leaf=""><span textstyle="">CD56+、高活化、快增殖</span></span></span><span><span leaf=""><span textstyle="">的独特亚群。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 脑转移微环境 vs. 外周原发瘤微环境（如肺癌/乳腺癌）</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">T细胞差异</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">数量减少</span></span></span><span><span leaf=""><span textstyle="">：脑转移中CD8+ T细胞比外周原发瘤少，且TCR克隆多样性降低（尽管转移瘤突变负荷更高）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NK细胞功能受损</span></span></span><span><span leaf=""><span textstyle="">：脑转移中NK细胞</span></span></span><span><span leaf=""><span textstyle="">CD56表达下调</span></span></span><span><span leaf=""><span textstyle="">，提示功能抑制。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">B细胞异质性</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肺腺癌原发灶与转移灶B细胞比例相似，但乳腺癌脑转移中B细胞</span></span></span><span><span leaf=""><span textstyle="">显著减少</span></span></span><span><span leaf=""><span textstyle="">。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">髓系细胞变化</span></span></span><span><span leaf=""><span textstyle="">：脑转移中中性粒细胞浸润更显著，且MDMs表型受脑组织定位驱动（与原发瘤类型无关）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 治疗启示</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向脑转移特异性免疫抑制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抑制MDMs的促转移表型（如CSF1R抑制剂）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">逆转NK细胞功能（如IL-15激动剂）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">利用区域一致性</span></span></span><span><span leaf=""><span textstyle="">：脑转移中TCR库跨区域一致性较高，提示共享抗原可能成为免疫治疗靶点。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">个体化策略</span></span></span><span><span leaf=""><span textstyle="">：乳腺癌与肺癌脑转移的B细胞差异提示需按原发瘤类型调整治疗。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：脑转移的免疫微环境兼具脑组织特异性（如MDMs主导）和原发瘤驱动特征（如B细胞差异），需通过跨部位免疫图谱分析指导精准治疗。</span></span></span></p><h3><span><span leaf=""><span textstyle="">B. 脑转移瘤（BrM）免疫组成与表型的决定因素及调节机制</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. 肿瘤来源的核心驱动作用</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">原发瘤类型决定免疫特征</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">乳腺癌BrM</span></span></span><span><span leaf=""><span textstyle="">：TAMs浸润为主，淋巴细胞浸润较少（"冷肿瘤"表型）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">肺癌BrM</span></span></span><span><span leaf=""><span textstyle="">：T细胞（尤其CD8+）浸润较高。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span><span><span leaf=""><span textstyle="">：B细胞和CD8+ T细胞富集（"热肿瘤"倾向），预后较好。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">突变谱的调控效应</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">TP53突变</span></span></span><span><span leaf=""><span textstyle="">（肺癌BrM）：促进免疫细胞增殖转录特征，但伴随髓系免疫抑制（如TAMs）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">高突变负荷乳腺癌BrM</span></span></span><span><span leaf=""><span textstyle="">：引发炎症性微环境（TAMs、中性粒细胞、CD8+ T细胞增多）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 脑组织微环境的调节特性</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">空间异质性</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span><span><span leaf=""><span textstyle="">：T细胞富集于肿瘤边缘。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NSCLC BrM</span></span></span><span><span leaf=""><span textstyle="">：T细胞倾向于间质浸润。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">TAMs可分布在瘤周区、瘤内或两者兼具。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫适应现象</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MDMs在脑内获得小胶质细胞样表型，但单核-巨噬细胞转化仍受原发瘤类型影响。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 患者个体化因素</span></span></span><page></page></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">年龄影响</span></span></span><span><span leaf=""><span textstyle="">：年轻患者中性粒细胞、DC和CD4+ T细胞浸润更多。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">治疗干预</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗</span></span></span><span><span leaf=""><span textstyle="">：晚期放疗可短暂减少髓系细胞，使TAMs中小胶质细胞比例回升（因MDMs更易受损）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫治疗</span></span></span><span><span leaf=""><span textstyle="">：可能改变T/B细胞比例（如PD-1抑制剂促进B细胞增殖）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 治疗策略启示</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">原发瘤导向的精准治疗</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">乳腺癌BrM：靶向TAMs（如CSF1R抑制剂）联合免疫激活剂。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">黑色素瘤BrM：优先考虑免疫检查点抑制剂（响应率可能更高）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">动态监测免疫变化</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗后髓系细胞减少的时间窗口或可联合免疫治疗。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">突变谱（如TP53）可能预测免疫微环境特征，指导靶向选择。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：脑转移的免疫表型由"原发瘤基因特征"和"脑组织微环境"共同塑造，并受患者个体因素及治疗史动态调控。未来需结合多组学分析实现个体化免疫治疗。</span></span></span></p><h2><span><span leaf=""><span textstyle="">四、靶向转移瘤TME的治疗策略</span></span></span><span></span></h2><h3><span><span leaf=""><span textstyle="">A. TAMs</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. TAMs的双面性：治疗靶点的基础</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">促瘤作用</span></span></span><span><span leaf=""><span textstyle="">：支持血管生成、免疫抑制、促进肿瘤侵袭</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抗瘤潜力</span></span></span><span><span leaf=""><span textstyle="">：抗原提呈、吞噬肿瘤细胞、激活T细胞</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向优势</span></span></span><span><span leaf=""><span textstyle="">：高浸润性、毗邻T细胞的定位、表型可塑性</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 当前两大治疗方向</span></span></span></h4><p><span><span leaf=""><span textstyle="">（1）TAM清除策略</span></span></span><span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CSF1R抑制剂</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">在黑色素瘤模型中阻止脑转移定植，但乳腺癌模型中因CSF2R/STAT5代偿激活导致疗效短暂</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">联合阻断</span></span></span><span><span leaf=""><span textstyle="">：CSF1R+STAT5双重抑制可延长肿瘤控制</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">副作用</span></span></span><span><span leaf=""><span textstyle="">：诱导类似神经退行性疾病的TAM表型</span></span></span></p><p><span><span leaf=""><span textstyle="">（2）TAM重编程策略</span></span></span><span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">TLR9激动剂（如CPG-C）</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">激活小胶质细胞吞噬功能，预防脑转移建立</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">STAT6/KLF4通路抑制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">阻断抗炎型TAMs，抑制乳腺癌脑转移生长</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">STING通路</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">在胶质瘤中显示抗瘤效果，但在脑转移中可能促进转移（需谨慎评估）</span></span></span></p><p><span><span leaf=""><span textstyle="">（3）新型协同靶点</span></span></span><span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MIF-CD74轴抑制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">阻断巨噬细胞趋化，联合放疗增强抗NSCLC脑转移效果</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">体外实验显示可促进小胶质细胞向迁移/吞噬表型转化</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 挑战与优化方向</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">时空特异性</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">早期靶向TAMs可能阻断转移定植，晚期需联合免疫治疗克服代偿机制</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">精准调控</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">避免完全清除TAMs（可能破坏CNS稳态），侧重表型转换</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">联合治疗</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CSF1Ri+放疗/免疫检查点抑制剂</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">MIF抑制剂+抗血管生成药物</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 临床转化前景</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">生物标志物开发</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CSF2R/STAT5激活状态预测CSF1Ri耐药</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CD74表达水平指导MIF靶向治疗</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">递送系统优化</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">纳米载体突破血脑屏障，靶向瘤内TAMs</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：靶向TAMs需平衡清除与功能重编程，联合策略和时序干预是关键。未来需结合脑转移亚型（如乳腺癌vs黑色素瘤）设计精准治疗方案。</span></span></span></p><h3><span><span leaf=""><span textstyle="">B. T细胞</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. 脑转移的免疫微环境特征与治疗分类</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">"热肿瘤"属性</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">与胶质瘤等"冷肿瘤"不同，脑转移（BrM）具有显著的淋巴细胞浸润（如CD8+ T细胞）和PD-L1表达，提示预存抗肿瘤免疫。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">治疗优势</span></span></span><span><span leaf=""><span textstyle="">：适合免疫检查点抑制剂（ICI）等T细胞导向疗法。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 免疫检查点抑制剂的临床进展</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">单药/联合治疗数据</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><table><tbody><tr><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">治疗方案</span></span></span><span></span></p></td><td data-colwidth="121" width="121" valign="top"><p><span><span leaf=""><span textstyle="">适应症</span></span></span><span></span></p></td><td data-colwidth="112" width="112" valign="top"><p><span><span leaf=""><span textstyle="">颅内缓解率</span></span></span><span></span></p></td><td data-colwidth="134" width="134" valign="top"><p><span><span leaf=""><span textstyle="">生存获益</span></span></span><span></span></p></td><td data-colwidth="87" width="87" valign="top"><p><span><span leaf=""><span textstyle="">不良反应率</span></span></span><span></span></p></td></tr><tr><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">帕博利珠单抗</span></span></span><span><span leaf=""><span textstyle="">（PD1）</span></span></span></p></td><td data-colwidth="121" width="121" valign="top"><p><span><span leaf=""><span textstyle="">多癌种BrM（未治疗/经治）</span></span></span></p></td><td data-colwidth="112" width="112" valign="top"><p><span><span leaf=""><span textstyle="">~40%</span></span></span></p></td><td data-colwidth="134" width="134" valign="top"><p><span><span leaf=""><span textstyle="">部分患者生存&gt;2年</span></span></span></p></td><td data-colwidth="87" width="87" valign="top"><p><span><span leaf=""><span textstyle="">&gt;50%</span></span></span></p></td></tr><tr><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">纳武利尤+伊匹木</span></span></span><span><span leaf=""><span textstyle="">（PD1+CTLA4）</span></span></span><page></page></p></td><td data-colwidth="121" width="121" valign="top"><p><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span></p></td><td data-colwidth="112" width="112" valign="top"><p><span><span leaf=""><span textstyle="">46%-57%</span></span></span></p></td><td data-colwidth="134" width="134" valign="top"><p><span><span leaf=""><span textstyle="">显著延长无进展生存期（PFS）</span></span></span></p></td><td data-colwidth="87" width="87" valign="top"><p><span><span leaf=""><span textstyle="">&gt;50%</span></span></span></p></td></tr><tr><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">纳武利尤+瑞拉利尤</span></span></span><span><span leaf=""><span textstyle="">（PD1+LAG3）</span></span></span></p></td><td data-colwidth="121" width="121" valign="top"><p><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span></p></td><td data-colwidth="112" width="112" valign="top"><p><span><span leaf=""><span textstyle="">数据待完善</span></span></span></p></td><td data-colwidth="134" width="134" valign="top"><p><span><span leaf=""><span textstyle="">较单药延迟BrM发生时间</span></span></span></p></td><td data-colwidth="87" width="87" valign="top"><p><span><span leaf=""><span textstyle="">可控</span></span></span></p></td></tr></tbody></table><p><span leaf=""><br></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">挑战</span></span></span><span><span leaf=""><span textstyle="">：高不良反应率（如免疫相关脑炎）需平衡疗效与安全性。</span></span></span></p><h4><span><span leaf=""><span textstyle="">3. 联合治疗新策略</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向+免疫协同</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">CDK4/6抑制剂（如阿贝西利）</span></span></span><span><span leaf=""><span textstyle="">：通过调控细胞周期增强PD1抑制剂敏感性（黑色素瘤BrM模型）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗/化疗</span></span></span><span><span leaf=""><span textstyle="">：可能释放肿瘤抗原，改善T细胞应答。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">时序优化</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">新辅助免疫治疗</span></span></span><span><span leaf=""><span textstyle="">：原发瘤存在时，外周T细胞可能预先被新抗原激活，增强后续对BrM的杀伤（临床前模型支持）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. T细胞功能调控的瓶颈与突破</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">T细胞耗竭</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">BrM中CD8+ T细胞高表达PD1、TIM3等，但部分对非肿瘤抗原反应（需联合表观遗传调控或细胞因子激活）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">抗原特异性限制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">低反应性T细胞与外周群体重叠度高，提示需增强肿瘤抗原提呈（如DC疫苗）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">5. 未来方向</span></span></span><page></page></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">生物标志物开发</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">PD-L1表达、TMB、T细胞克隆多样性预测ICI响应。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">局部递送技术</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">鞘内注射CAR-T或双特异性抗体（如PSMAxCD3）减少全身毒性。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">新型靶点探索</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">LAG3、TIGIT等次代免疫检查点联合PD1/CTLA4。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：BrM的"热肿瘤"特性为T细胞免疫治疗提供基础，但需通过联合策略、时序优化和精准患者选择克服耗竭与毒性。原发瘤与转移灶的免疫协同机制是未来研究重点。</span></span></span></p><h3><span><span leaf=""><span textstyle="">C. 脑转移联合治疗策略：现状与未来方向</span></span></span><span></span></h3><h4><span><span leaf=""><span textstyle="">1. 联合治疗的理论基础</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">免疫微环境异质性</span></span></span><span><span leaf=""><span textstyle="">：脑转移瘤（BrM）存在从"热肿瘤"（T细胞浸润）到"冷肿瘤"（免疫排斥）的连续谱系，单一疗法效果有限。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">协同机制</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗</span></span></span><span><span leaf=""><span textstyle="">：释放肿瘤抗原、增加T细胞浸润，但可能诱发PD-L1+髓系细胞代偿性增多。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">化疗</span></span></span><span><span leaf=""><span textstyle="">：诱导免疫原性细胞死亡，与PD-L1抑制剂（如阿替利珠单抗）联用可提升NSCLC BrM颅内缓解率至45%。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向治疗</span></span></span><span><span leaf=""><span textstyle="">：如BRAF抑制剂联合免疫治疗，需注意给药时序（免疫治疗后续更优）。</span></span></span></p><h4><span><span leaf=""><span textstyle="">2. 现有联合方案临床证据</span></span></span></h4><table><tbody><tr><td data-colwidth="161" width="161" valign="top"><p><span><span leaf=""><span textstyle="">联合方案</span></span></span><span></span></p></td><td data-colwidth="89" width="89" valign="top"><p><span><span leaf=""><span textstyle="">适应症</span></span></span><span></span></p></td><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">关键疗效</span></span></span><span></span></p></td><td data-colwidth="204" width="204" valign="top"><p><span><span leaf=""><span textstyle="">机制</span></span></span><span></span></p></td></tr><tr><td data-colwidth="161" width="161" valign="top"><p><span><span leaf=""><span textstyle="">放疗+免疫治疗</span></span></span><span></span><page></page></p></td><td data-colwidth="89" width="89" valign="top"><p><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span></p></td><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">生存期较单纯放疗延长（Meta分析支持）</span></span></span></p></td><td data-colwidth="204" width="204" valign="top"><p><span><span leaf=""><span textstyle="">远隔效应（abscopal effect）：辐射区外免疫激活，BBB通透性改变促进免疫细胞浸润</span></span></span></p></td></tr><tr><td data-colwidth="161" width="161" valign="top"><p><span><span leaf=""><span textstyle="">化疗+PD-L1抑制剂</span></span></span><span></span></p></td><td data-colwidth="89" width="89" valign="top"><p><span><span leaf=""><span textstyle="">NSCLC BrM</span></span></span></p></td><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">中位生存延长12个月（vs 单纯化疗）</span></span></span></p></td><td data-colwidth="204" width="204" valign="top"><p><span><span leaf=""><span textstyle="">化疗增强肿瘤抗原释放，PD-L1阻断解除T细胞抑制</span></span></span></p></td></tr><tr><td data-colwidth="161" width="161" valign="top"><p><span><span leaf=""><span textstyle="">立体定向放疗+伊匹木单抗</span></span></span><span></span></p></td><td data-colwidth="89" width="89" valign="top"><p><span><span leaf=""><span textstyle="">黑色素瘤BrM</span></span></span></p></td><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">显著提高生存率</span></span></span></p></td><td data-colwidth="204" width="204" valign="top"><p><span><span leaf=""><span textstyle="">放疗后4周内给免疫治疗时机最佳</span></span></span></p></td></tr><tr><td data-colwidth="161" width="161" valign="top"><p><span><span leaf=""><span textstyle="">靶向+免疫</span></span></span><span><span leaf=""><span textstyle="">（如BRAFi+PD1）</span></span></span></p></td><td data-colwidth="89" width="89" valign="top"><p><span><span leaf=""><span textstyle="">BRAF突变黑色素瘤</span></span></span></p></td><td data-colwidth="147" width="147" valign="top"><p><span><span leaf=""><span textstyle="">序贯治疗优于同步</span></span></span></p></td><td data-colwidth="204" width="204" valign="top"><p><span><span leaf=""><span textstyle="">靶向治疗减轻肿瘤负荷后，免疫治疗更易起效</span></span></span></p></td></tr></tbody></table><p><span leaf=""><br></span></p><h4><span><span leaf=""><span textstyle="">3. 时序优化与挑战</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗与免疫的时序</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">最佳窗口</span></span></span><span><span leaf=""><span textstyle="">：放疗后4周内启动免疫治疗（黑色素瘤BrM数据）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">逆向时序</span></span></span><span><span leaf=""><span textstyle="">（免疫治疗后放疗）可能降低疗效。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">副作用管理</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗+免疫联合的神经毒性（如脑水肿）需密切监测。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">化疗+免疫的血液学毒性叠加风险。</span></span></span></p><h4><span><span leaf=""><span textstyle="">4. 新兴策略与临床试验</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">NK细胞联合化疗</span></span></span><span><span leaf=""><span textstyle="">（NCT05588453）：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">化疗清除免疫抑制细胞，NK细胞提供直接杀伤。</span></span></span><page></page></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">三重联合</span></span></span><span><span leaf=""><span textstyle="">（肿瘤靶向+TME调控+免疫）：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">例如：CSF1R抑制剂（靶向TAMs）+放疗+PD1抑制剂（临床前数据支持）。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">局部递送技术</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">鞘内注射免疫药物（如CAR-T）减少全身毒性。</span></span></span></p><h4><span><span leaf=""><span textstyle="">5. 未来方向</span></span></span></h4><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">生物标志物开发</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">放疗后PD-L1动态变化、TCR克隆扩增预测联合疗效。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">微环境重编程</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">靶向IDO、TGF-β等免疫抑制通路，联合ICI逆转"冷肿瘤"。</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">跨癌种差异</span></span></span><span><span leaf=""><span textstyle="">：</span></span></span></p><p><span><span leaf=""><span textstyle="">●</span></span><span></span></span><span><span leaf=""><span textstyle="">乳腺癌BrM（低浸润）需优先联合TAMs调控，黑色素瘤BrM（高浸润）侧重免疫激活。</span></span></span></p><p><span><span leaf=""><span textstyle="">总结</span></span></span><span><span leaf=""><span textstyle="">：脑转移联合治疗需基于免疫分型（热/冷）选择策略，注重时序优化和毒性管理。未来需探索微环境重编程三联疗法及个体化生物标志物。</span></span></span></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/NfBXJMHZI_Ls391NZOyzNA",target="_blank" rel="noopener noreferrer">原文链接</a>
